Loading... Please wait...
Sort by:

FirstWord Generics/Biosimilar Reports

 

  • Digital Health and the Management of Chronic Disease
    Learn More Digital Health and the Management of Chronic Disease
    Essential strategies for developing next phase digital health solutions The COVID-19 pandemic has accelerated and elevated the role of digital health and could serve as a turning point for digital platforms to become...
  • Measuring Digital Success in Pharma: Essential KPIs
    Learn More Measuring Digital Success in Pharma: Essential KPIs
    Which KPI's should pharma be using to assess the success of its digital technology investments? The Covid-19 pandemic is fundamentally changing working practice and driving immediate expansion of digital solutions. But...
  • Biosimilars: US Payer Insights 2020
    Learn More Biosimilars: US Payer Insights 2020
    What do payers see as unlocking the sluggish US biosimilar market? Despite the availability of biosimilar versions of Avastin, Herceptin and Rituxan, payers are not pleased with the development within this sector...
  • Drivers of Non-medical Rx Switching
    Learn More Drivers of Non-medical Rx Switching
    The strategies that are promoting wider use of biosimilars Payers are highly motivated to realise the cost savings of biosimilars, but what strategies are they using to reassure and encourage physicians and patients?...
  • Trends in Digital Physician Engagement
    Learn More Trends in Digital Physician Engagement
    Next level opportunities for developing physician relationships across pharma's business Digital technology has transformed pharma's communications with often difficult to engage physicians. But merely having a suite of...
  • Trends in Digital Patient Engagement
    Learn More Trends in Digital Patient Engagement
    Embedding digital patient engagement throughout the patient journey Pharma companies have made good progress with digital delivery within innovative patient support programs—but there is still significant scope to...
  • Biosimilars: Go-to-Market Case Studies
    Learn More Biosimilars: Go-to-Market Case Studies
    As the biosimilar sector matures, what are the key issues that are shaping commercial strategies? As physician and payer confidence in the use of biosimilars grows, US and European companies are having to rethink their...
  • Digital Technologies: New Strategies for Customer Engagement
    Learn More Digital Technologies: New Strategies for Customer Engagement
    Digital technology is transforming customer engagement Pharma has embraced the digital revolution with open arms—clearly it offers exciting new opportunities for customer engagement. But initial enthusiasm...
  • Market Access for Cell and Gene Therapies
    Learn More Market Access for Cell and Gene Therapies
    Pharma challenged to rethink its market access strategies While the promise of cell and gene therapy (C&GT) to deliver enduring or even curative treatments is welcomed there is no long-term market experience and...
  • Partnering in Digital Health: Pharma and Tech Companies
    Learn More Partnering in Digital Health: Pharma and Tech Companies
    The secret of successful digital health partnerships Digital health is guaranteed to play a huge part in the future of pharma. Innovative technology that can improve patient access, increase quality of care, boost...
  • Paying for Digital Health: Payer Insights (2019)
    Learn More Paying for Digital Health: Payer Insights (2019)
    Which digital health technologies are exciting payers? How and where can digital health technology improve patient outcomes and save payers money? Across the digital health field there are hundreds of applications...
  • Pricing and Reimbursement in Oncology
    Learn More Pricing and Reimbursement in Oncology
    Payers want pharma to address the challenges they face Specialised cancer therapies such as checkpoint inhibitors have significantly improved outcomes for patients—but for payers they represent a growing pricing...
  • Real World Evidence: The Role of Medical Affairs
    Learn More Real World Evidence: The Role of Medical Affairs
    How well has RWE integrated into Medical Affairs—and should more be done? Payers and other stakeholders increasingly expect to see real world evidence (RWE) to support their decision making. Since being added to...
  • The Role of Patient Journey Mapping in Patient Engagement
    Learn More The Role of Patient Journey Mapping in Patient Engagement
    Are you employing the latest technology and techniques to power your patient journey mapping? "Pharma companies first need to understand that their task is not to produce new product; their task is to provide a really...
  • Biomarkers and Companion diagnostics: Payer Insights
    Learn More Biomarkers and Companion diagnostics: Payer Insights
    What do you need to do to get payer support for companion diagnostics and biomarkers? The investment decisions made by the biggest players in core disease areas drive market trends—so it's crucial to understand...
  • Trends in Investment by Big Pharma
    Learn More Trends in Investment by Big Pharma
    What direction are big pharma investments taking? The investment decisions made by the biggest players in core disease areas drive market trends—so it's crucial to understand where the big money is going and why...
  • Biosimilars: The Importance of Real-World Evidence (2019)
    Learn More Biosimilars: The Importance of Real-World Evidence (2019)
    Are you generating the right RWE to influence the right stakeholders? As the biosimilar sector continues to evolve and experience of their use deepens, what role should real-world evidence (RWE) now take in stakeholder...
  • Biosimilars: US Payer Insights (2019)
    Learn More Biosimilars: US Payer Insights (2019)
    What do payers see as critical to unlocking the stalled US biosimilar sector? How do payers view the trends in the sluggish US biosimilar market and what initiatives do they want from pharma? Originator companies are...
  • Pharma-Tech Partnerships: Key Success Factors
    Learn More Pharma-Tech Partnerships: Key Success Factors
    What does an ideal Pharma-Tech partnership look like? Learn from Merck, Sanofi, Boehringer Ingelheim and UCB With tech companies making their presence felt in the health market and a demand for greater efficiency...
  • Commercialisation of Biosimilars: Current Best Practice and Future Trends
    Learn More Commercialisation of Biosimilars: Current Best Practice and Future Trends
    The key to commercial success for biosimilars? Find out what the experts say The biosimilars market is in a state of flux as key players in the US and Europe actively seek to improve perceptions, shape the market, and...

customer.service@firstwordpharma.com

All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved